{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T05:25:37Z","timestamp":1697520337256},"reference-count":46,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2744,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p>Abstract: <jats:italic>Objectives<\/jats:italic>:\u2002Recombinant human erythropoietin (rHuEpo) improves anemia in 25% of patients with myelodysplastic syndromes (MDS). The variable and sometimes low response rate to rHuEpo treatment raises the question whether the existence of autoantibodies against erythropoietin (epo) is partially responsible. In the present study we investigated the presence of anti\u2010epo autoantibodies in MDS patients. <jats:italic>Methods<\/jats:italic>:\u2002Forty\u2010three patients with MDS were studied. Sixteen patients had refractory anemia (RA), 13 had RA with ringed sideroblasts, 3 had RA with excess of blasts (RAEB), 9 had RAEB in transformation and 2 patients had chronic myelomonocytic leukemia. They were divided in 3 groups according to rHuEpo treatment. Group A consisted of 10 patients who did not receive rHuEpo treatment. Group B included 13 patients who were on rHuEpo treatment (150 IU\/kg subcutaneously, 3 times weekly) showing an increase of hemoglobin (Hb) values or reduction of transfusion requirements and Group C consisted of 20 patients who did not respond or stopped responding to rHuEpo treatment. Laboratory studies consisted of a complete blood cell count, measurement of serum epo and determination of anti\u2010epo antibodies using ELISA. <jats:italic>Results<\/jats:italic>:\u2002There were no significant differences with regard to age and sex among the three groups. No autoantibodies against epo were found in the examined sera, apart from a female patient from group A who showed a low positive titer. <jats:italic>Conclusion<\/jats:italic>:\u2002We suggest that anti\u2010epo autoantibodies do not contribute to the development of MDS\u2010related anemia and are not responsible for the modest response to rHuEpo treatment. Further investigation is needed to identify possible reasons for the low response rate to rHuEpo treatment.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2001.00336.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T18:50:32Z","timestamp":1047408632000},"page":"31-36","source":"Crossref","is-referenced-by-count":6,"title":["Investigation for the presence of anti\u2010erythropoietin antibodies in patients with myelodysplastic syndromes"],"prefix":"10.1111","volume":"66","author":[{"given":"Paraskevi V.","family":"Voulgari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftheria ChR.","family":"Hatzimichael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavroula","family":"Tsiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Tzallas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros A.","family":"Drosos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos L.","family":"Bourantas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(92)90054-T"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1182\/blood.V88.11.4275.4275","article-title":"Altered oncoprotein expression and apoptosis in myelodysplastic syndrome bone marrow cells","volume":"88","author":"Rajapaksa R","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood.V88.7.2640.bloodjournal8872640","article-title":"Indication of an involvement of interleukin\u20101 beta converting enzyme\u2010like protease in intramedullary apoptotic cell death in the bone marrow of patients wit myelodysplastic syndromes","volume":"88","author":"Mundle SD","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_5_2","first-page":"161","article-title":"Myelodysplastic syndromes. [Review]","volume":"151","author":"Doll DC","year":"1989","journal-title":"West J Med"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"The French\u2013American\u2013British (FAB) co\u2010operative group: proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett JM","year":"1982","journal-title":"Br J Haematol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.7.1658.1658"},{"key":"e_1_2_6_8_2","first-page":"466","article-title":"Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand","volume":"10","author":"Backx B","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(96)00002-1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01539.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.5.1690"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08421.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood.V92.1.68.413k23_68_75","article-title":"Treatment of anemia in myelodysplastic syndromes with granulocyte colony\u2010stimulating factor plus erythropoietin: results from a randomized phase II study and long term follow\u2010up of 71 patients","volume":"92","author":"Hellstrom\u2013lindberg E","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.10.4076.bloodjournal87104076"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4013211.x"},{"key":"e_1_2_6_16_2","first-page":"1058","article-title":"for the Spanish Erythropathology Group. Erythropoietin plus granulocyte colony\u2010stimulating factor in the treatment of myelodysplastic syndromes. Indetification of a subgroup of responders","volume":"84","author":"Remacha AF","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401442"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603073341004"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401216"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009749950154293"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/315156"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-93-2-347"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905273402107"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01697619"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00708.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0925-5710(96)00455-0"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.V77.2.413.413","article-title":"Increased levels of soluble interleukin\u20102 receptors and tumor necrosis factor in serum of patients with myelodysplastic syndromes","volume":"77","author":"Zoumbos N","year":"1991","journal-title":"Blood"},{"key":"e_1_2_6_28_2","first-page":"265","article-title":"Low serum levels of tumor necrosis factor and interleukin\u20101 beta in myelodysplastic syndromes responsive to recombinant erythropoietin","volume":"79","author":"Musto P","year":"1994","journal-title":"Haematologica"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1997.tb00007.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041650312"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-8652(199901)60:1<36::aid-ajh7>3.0.co;2-#"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01703232"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(91)90025-O"},{"key":"e_1_2_6_34_2","first-page":"36","article-title":"Clinical application of recombinant erythropoietin in myelodysplasia","volume":"76","author":"Mittelman M","year":"1990","journal-title":"Hematol Oncol Clin North Am"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08421.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08909.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1006\/phrs.1999.0593"},{"key":"e_1_2_6_38_2","first-page":"331","article-title":"Antibodies to recombinant human erythropoientin causing pure red cell aplasia","volume":"47","author":"Prabhakar SS","year":"1997","journal-title":"Clin Nephrol"},{"key":"e_1_2_6_39_2","first-page":"253","article-title":"Relationship between autoantibody and dermatosis in myelodysplastic syndrome","volume":"25","author":"Shimamoto Y","year":"1993","journal-title":"Haematologia"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb07504.x"},{"key":"e_1_2_6_41_2","first-page":"343","article-title":"Autoimmune hemolytic anemia and myelodysplastic syndromes","volume":"34","author":"Martin Vega C","year":"1989","journal-title":"Sangre"},{"key":"e_1_2_6_42_2","first-page":"177","article-title":"Immunohematologic study in 112 patients with myelodysplastic syndromes: 10\u2010year analysis","volume":"40","author":"Arriaga F","year":"1995","journal-title":"Sangre"},{"key":"e_1_2_6_43_2","first-page":"593","article-title":"Malignant lymphoma complicating myelodysplastic syndrome with autoantibody for the thyroid gland","volume":"38","author":"Kondo H","year":"1997","journal-title":"Rinsho Ketsueki"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v31.pm9469507"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.6322262.x"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0925-5710(97)00042-x"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.37.973"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2001.00336.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2001.00336.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2001.00336.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T01:29:43Z","timestamp":1697506183000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2001.00336.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1034\/j.1600-0609.2001.00336.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2001.00336.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}